Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.

Structured Finance

The product image can not be displayed.
Coverage of asset classes ranging from the traditional, such as mortgages, autos and credit cards, to evolving classes, such as intellectual property and collateralized debt obligations. 


  • 23 Nov 2015
    • Moody’s looks at the US government’s income-based repayment plan for FFELP loans
      This report looks at the US government’s Income-Based Repayment (IBR) plan, the only repayment plan directly available to borrowers of government-backed loans issued through the Federal Family Education Loan Program (FFELP). The report explains who can qualify for IBR, how payments are calculated and under what conditions the loans will be forgiven... Press Release l Full Report
  • 18 Nov 2015
    • Cross-Sector Global: 2016 Outlook - Credit Conditions Stable but Downside Risks Increase
      Our outlook for global credit conditions in 2016 is stable overall, but downside risks are greater than a year ago. Four broad trends create varying credit risks, as well as some benefits, for corporates, financials, infrastructure issuers, sovereigns and sub-sovereigns, and structured financings: an eventual rise in US interest rates, low oil and commodity prices, China’s economic slowdown and persistently slow growth in Europe. Other emerging risks will arise from geopolitical crises, environmental challenges and declining asset quality… Full Report
    • Side Effects of Pharma Price Scrutiny Will Stem CLO Gains from M&A Activity
      Recent scrutiny of Valeant Pharmaceuticals International Inc.’s and other drug companies’ pricing practices likely will curtail some of the gains collateralized loan obligations (CLOs) have made on merger and acquisition activity in the generic and specialty pharmaceutical sector. CLOs have indirectly benefited from M&A through deleveraging in amortizing CLOs and low risk par building in reinvesting CLOs. The scrutiny raises credit risks for generic and specialty pharmaceutical companies, and will slow M&A activity going forward... Full Report
Indices & Data
Please refine your search by Market Segment to get corresponding Rating Activity and Watchlist
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry
    © 2015 Moody's Investors Service, Inc., Moody’s Analytics, Inc. and/or their affiliates and licensors. All rights reserved.
    Regional Sites: